Clearmind Medicine to Host “Psychedelics for Alcoholism” Virtual Educational Event on October 20


Panel of Experts to Present and Discuss Potential New Treatments for Alcohol Use Disorder and Heavy Alcohol Use

TORONTO, October 01, 2021 (GLOBE NEWSWIRE) – via InvestorWire – Clearmind Medicine Inc. (CSE: CMND) (“Clear mind“or the”Society“), a psychedelic medicine biotechnology company focused on the discovery and development of novel therapies derived from psychedelics to solve widespread and under-treated health problems, is pleased to announce that it will host Psychedelics for alcoholism, a free, live virtual event highlighting potential new treatments for alcohol use disorders and binge drinking.

The online event will take place on October 20, 2021, starting at 12 p.m. EST / 9 a.m. PST; registration is open and free to all. The event will feature short presentations by featured speakers, followed by a discussion with a question-and-answer session.

The company organized a panel of scientists, thought leaders, therapists and experts to share their experiences and educate participants on the growing evidence suggesting the effectiveness of psychedelics, and in particular MEAI, in regulating excessive alcohol consumption.

Company representatives will also provide an update on Clearmind’s MEAI-based drugs and their potential for the treatment of alcohol use disorders and heavy drinking.

Adi Zuloff-Shani, Ph.D., CEO of Clearmind, said: WeWe are in the midst of a psychedelic renaissance that is revolutionizing the way we deal with mental disorders. We organized this event to raise awareness of the progress being made in the field, and more specifically to raise awareness of Clearmind’s work on alcohol and binge drinking.

“Along with our sponsors and partners, we look forward to sharing our progress and providing access to accurate information to interested communities, including mental health practitioners, researchers, potential patients, investors and the general public. “ Zuloff-Shani concluded.

Here is a list of our panelists and partners. To register for the event or learn more about psychedelics for alcoholism, visit the event website.

Among our featured speakers and panelists: Shannon Smadella, moderator; Adi Zuloff Shani, Ph.D., Managing Director of Clearmind; Marc Haden, advisory board member, Clearmind; Terri Freeland, construction industry professional; and Dr Jeff Morley, licensed psychologist.

Partners include: Canadian Psychedelic Association, World Psychedelics Day, McKenna Academy of Natural Philosophy â„¢, and Global overview.

About Clearmind Medicine Inc.

Clearmind (CSE: CMND) is a psychedelic pharmaceutical biotechnology company focused on the discovery and development of novel therapies derived from psychedelics to address widespread and underserved health problems, including alcohol use disorders. Its main objective is to research and develop compounds based on psychedelics and to attempt to market them as regulated drugs, foods or supplements.

The Company’s intellectual portfolio currently consists of two families of patents. The first, “Binge Behavior Regulators” has been granted in the United States, Europe, China and India, with pending divisional applications in Europe and the United States. The second, “Alcohol Beverage Substitute”, has been approved for a European patent, with applications in the United States, China and India. The Company intends to apply for additional patents for its compounds whenever warranted and will remain opportunistic in acquiring additional intellectual property to build its portfolio.

Clearmind’s shares are listed for trading on the Canadian Securities Exchange under the symbol “CMND“and the Frankfurt Stock Exchange under the symbol”JCM0.

For more information, please contact:

Investor Relations Email:

[email protected]

Telephone: (778) 400-5347

General Inquiry Email:

[email protected]

www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This press release may contain forward-looking statements and information based on current expectations. These statements should not be interpreted as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those implied by such statements. These statements include submitting the relevant documentation on time to the satisfaction of the relevant regulators and raising sufficient funds to carry out the Company’s business strategy. There is no certainty that any of these events will occur. Although these statements are based on reasonable assumptions of management, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing in early stage companies inherently involves a high degree of risk, and investing in securities of the Company will be considered highly speculative.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of securities in any province where such an offer, solicitation or sale would be illegal. The securities issued or to be issued under the private placement have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States upon lack of registration or applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CST”) Nor its regulatory services provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Contact wire service
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
[email protected]

About Rhonda Lee

Check Also

Mycobacterium abscessus pneumonia in severe alcoholism

In the USA, Mycobacterial tuberculosis the infection is not common and the infection rate has …

Leave a Reply

Your email address will not be published.